Unigene to Present at the Rodman & Renshaw 12th Annual Healthcare Conference

BOONTON, N.J.--(BUSINESS WIRE)-- Unigene Laboratories, Inc. (OTCBB: UGNE), a world leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced it will present at the Rodman & Renshaw 12th Annual Healthcare Conference at 2:50 p.m. Eastern Time on September 14, 2010, in New York, NY. Unigene's President and Chief Executive Officer Ashleigh Palmer will present on the Company's new corporate strategy and business development initiatives to enhance Unigene’s presence in the rapidly growing peptide space. A key component of this strategy is Unigene’s Peptelligence™ platform, representing a distinctive competence originating from the Company’s proprietary expertise and validated suite of patented peptide drug delivery and manufacturing technologies.

The presentation will be webcast. To access the live audio broadcast of the presentation, or the subsequent archived recording, log onto http://www.wsw.com/webcast/rrshq18/ugne. Please connect to the website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline, worldwide rights for its calcitonin manufacturing technology to Novartis and worldwide rights (except for China) for its oral calcitonin program to Tarsa Therapeutics, Inc. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin and PTH analogs. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 265-1100 or visit http://www.unigene.com. For information about Fortical, visit http://www.fortical.com.



CONTACT:

Unigene Laboratories, Inc.
William Steinhauer, 973-265-1100
VP of Finance
or
Burns McClellan
Justin Jackson (media)
212-213-0006
[email protected]
or
Michelle Szwarcberg (media)
212-213-0006
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.